Percheron Therapeutics Limited (ASX:PER)

Percheron Therapeutics Revenue

In the fiscal year ending June 30, 2026, Percheron Therapeutics had annual revenue of 843.60K AUD, down -53.16%. Percheron Therapeutics had revenue of 88.41K in the half year ending December 31, 2025, a decrease of -92.63%.

• Revenue: 843.60K
• Revenue Growth: -53.16%
• P/S Ratio: 9.93
• Revenue / Employee: 105.45K
• Employees: 8
• Market Cap: 8.37M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	843.60K	-957.46K	-53.16%
Jun 30, 2025	1.80M	-1.17M	-39.32%
Jun 30, 2024	2.97M	1.00M	51.07%
Jun 30, 2023	1.96M	186.87K	10.51%
Jun 30, 2022	1.78M	1.20M	207.72%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 20, 2026

Data Sources Report a data error